Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

RYAN E HALL

Allopathic & Osteopathic Physicians Internal Medicine Hematology & Oncology

NPI
1366761975
CMS profile
1028578
Location
LITTLE ROCK, AR

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2025 · Entire year

$88.44

5 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2025 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $88.44 5

By paying entity

PY2025 · entire year · sorted by reported total

Paying entityAmountRecords
Caris MPI, Inc. $29.22 2
GENZYME CORPORATION $20.86 1
Gilead Sciences, Inc. $19.22 1
Azurity Pharmaceuticals, Inc. $19.14 1

Page 1 of 1; records 1–5 of 5 matching records. This page contains 5 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

RYAN E HALL

NPI 1366761975 · CMS profile ID 1028578

Allopathic & Osteopathic Physicians / Internal Medicine / Hematology & Oncology

LITTLE ROCK, AR

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–5 of 5 matching records. This page contains 5 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1366761975?year=2025&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
RYAN E HALL, NPI 1366761975, CMS profile ID 1028578. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–5 of 5 matching records. This page contains 5 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1366761975?year=2025&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
APA 7
IndustryPayments. (2026). RYAN E HALL, NPI 1366761975, CMS profile ID 1028578. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–5 of 5 matching records. This page contains 5 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1366761975?year=2025&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
Bluebook
RYAN E HALL, NPI 1366761975, CMS profile ID 1028578, IndustryPayments, General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–5 of 5 matching records. This page contains 5 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e. https://industrypayments.org/provider/npi-1366761975?year=2025&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2025 · Physicians and non-physician practitioners · CMS publication 2026-06-30

5 matching records · $88.44 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 5 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–5 of 5.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Caris MPI, Inc. $15.4212/15/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1234280917 CMS
Caris MPI, Inc. $13.8012/01/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1234280915 CMS
Azurity Pharmaceuticals, Inc. $19.1411/11/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1242672014 CMS
GENZYME CORPORATION $20.8610/20/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1233624184 CMS
Gilead Sciences, Inc. $19.2205/08/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1234536450 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $416.26 6
PY2020 $99.00 1
PY2021 $24.68 2
PY2022 $1,019.78 7
PY2023 $2,636.63 8
PY2024 $382.04 5
PY2025 $88.44 5

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $741,878.53 46
PY2024 Principal investigator $292,913.76 72
PY2023 Principal investigator $1,493,338.71 38
PY2022 Principal investigator $500,825.07 28
PY2021 Principal investigator $491,385.16 69
PY2020 Recipient $139.26 1
PY2020 Principal investigator $518,626.07 135
PY2019 Principal investigator $72,202.28 102

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2020

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

136 records in PY2020

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 BeiGene, Ltd. $1,347.60 12/22/2020 Non-covered Recipient Entity
Central Arkansas Radiation Therapy Institute, Inc
A Phase 3, Randomized Study of Zanubrutinib (BGB-3111) Compared With Ibrutinib in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma No dispute reported 06/30/2026 752997279
Principal investigator 1 Pharmacyclics LLC, An AbbVie Company $250.00 12/22/2020 Non-covered Recipient Entity
Central Arkansas Radiation Therapy Institute Carti Computed Tomography
PCYC-1134M-CA No dispute reported 06/30/2026 727738445
Principal investigator 1 Pharmacyclics LLC, An AbbVie Company $250.00 12/22/2020 Non-covered Recipient Entity
Central Arkansas Radiation Therapy Institute Carti Computed Tomography
PCYC-1134M-CA No dispute reported 06/30/2026 727738449
Principal investigator 1 Pharmacyclics LLC, An AbbVie Company $250.00 12/22/2020 Non-covered Recipient Entity
Central Arkansas Radiation Therapy Institute Carti Computed Tomography
PCYC-1134M-CA No dispute reported 06/30/2026 727738453
Principal investigator 1 Pharmacyclics LLC, An AbbVie Company $250.00 12/22/2020 Non-covered Recipient Entity
Central Arkansas Radiation Therapy Institute Carti Computed Tomography
PCYC-1134M-CA No dispute reported 06/30/2026 727738519
Principal investigator 1 Merck Sharp & Dohme Corporation $1,503.12 12/21/2020 Non-covered Recipient Entity
CARTI CANCER CENTER
A Randomized Phase 3 Study Evaluating Cystectomy with Perioperative Pembrolizumab and Cystectomy with Perioperative Enfortumab Vedotin and Pembrolizumab versus Cystectomy Alone in Cisplatin-Ineligible Participants with Muscle-Invasive Bladder Cancer KEYNOTE-905,EV-303 No dispute reported 06/30/2026 740782279
Principal investigator 1 Merck Sharp & Dohme Corporation $13,027.98 12/17/2020 Non-covered Recipient Entity
CARTI CANCER CENTER
A Randomized Phase 3 Study Evaluating Cystectomy with Perioperative Pembrolizumab and Cystectomy with Perioperative Enfortumab Vedotin and Pembrolizumab versus Cystectomy Alone in Cisplatin-Ineligible Participants with Muscle-Invasive Bladder Cancer KEYNOTE-905,EV-303 No dispute reported 06/30/2026 740782277
Principal investigator 1 Pharmacyclics LLC, An AbbVie Company $250.00 12/15/2020 Non-covered Recipient Entity
Central Arkansas Radiation Therapy Institute Carti Computed Tomography
PCYC-1134M-CA No dispute reported 06/30/2026 727737177
Principal investigator 1 Pharmacyclics LLC, An AbbVie Company $250.00 12/15/2020 Non-covered Recipient Entity
Central Arkansas Radiation Therapy Institute Carti Computed Tomography
PCYC-1134M-CA No dispute reported 06/30/2026 727737181
Principal investigator 1 Pharmacyclics LLC, An AbbVie Company $250.00 12/15/2020 Non-covered Recipient Entity
Central Arkansas Radiation Therapy Institute Carti Computed Tomography
PCYC-1134M-CA No dispute reported 06/30/2026 727737185
Principal investigator 1 Pharmacyclics LLC, An AbbVie Company $250.00 12/15/2020 Non-covered Recipient Entity
Central Arkansas Radiation Therapy Institute Carti Computed Tomography
PCYC-1134M-CA No dispute reported 06/30/2026 727737999
Principal investigator 1 Pharmacyclics LLC, An AbbVie Company $250.00 12/15/2020 Non-covered Recipient Entity
Central Arkansas Radiation Therapy Institute Carti Computed Tomography
PCYC-1134M-CA No dispute reported 06/30/2026 727738029
Principal investigator 1 Pharmacyclics LLC, An AbbVie Company $250.00 12/15/2020 Non-covered Recipient Entity
Central Arkansas Radiation Therapy Institute Carti Computed Tomography
PCYC-1134M-CA No dispute reported 06/30/2026 727738033
Principal investigator 1 Pharmacyclics LLC, An AbbVie Company $250.00 12/15/2020 Non-covered Recipient Entity
Central Arkansas Radiation Therapy Institute Carti Computed Tomography
PCYC-1134M-CA No dispute reported 06/30/2026 727738397
Principal investigator 1 Pharmacyclics LLC, An AbbVie Company $250.00 12/15/2020 Non-covered Recipient Entity
Central Arkansas Radiation Therapy Institute Carti Computed Tomography
PCYC-1134M-CA No dispute reported 06/30/2026 727738409
Principal investigator 1 Pharmacyclics LLC, An AbbVie Company $250.00 12/15/2020 Non-covered Recipient Entity
Central Arkansas Radiation Therapy Institute Carti Computed Tomography
PCYC-1134M-CA No dispute reported 06/30/2026 727738638
Principal investigator 1 Pharmacyclics LLC, An AbbVie Company $250.00 12/15/2020 Non-covered Recipient Entity
Central Arkansas Radiation Therapy Institute Carti Computed Tomography
PCYC-1134M-CA No dispute reported 06/30/2026 727738645
Principal investigator 1 BeiGene, Ltd. $24,658.84 12/09/2020 Non-covered Recipient Entity
CARTI Cancer Center
A Phase 2, Multicenter, Single-arm Study of Zanubrutinib (BGB-3111) in Patients with Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Intolerant of Prior Treatment with Ibrutinib No dispute reported 06/30/2026 752997235
Principal investigator 1 BeiGene, Ltd. $61,647.10 11/30/2020 Non-covered Recipient Entity
CARTI Cancer Center
A Phase 2, Multicenter, Single-arm Study of Zanubrutinib (BGB-3111) in Patients with Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Intolerant of Prior Treatment with Ibrutinib No dispute reported 06/30/2026 752997233
Principal investigator 1 BeiGene, Ltd. $49,317.68 11/11/2020 Non-covered Recipient Entity
CARTI Cancer Center
A Phase 2, Multicenter, Single-arm Study of Zanubrutinib (BGB-3111) in Patients with Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Intolerant of Prior Treatment with Ibrutinib No dispute reported 06/30/2026 752997231
Principal investigator 1 BeiGene, Ltd. $3,067.20 11/10/2020 Non-covered Recipient Entity
Central Arkansas Radiation Therapy Institute, Inc
A Phase 3, Randomized Study of Zanubrutinib (BGB-3111) Compared With Ibrutinib in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma No dispute reported 06/30/2026 752997283
Principal investigator 1 Seagen Inc. $5,500.00 11/03/2020 Non-covered Recipient Entity
CENTRAL ARKANSAS RADIATION THERAPY INSTITUTE
Open-label, Randomized, Controlled Phase 3 Study of Enfortumab Vedotin in Combination With Pembrolizumab With or Without Chemotherapy, Versus Chemotherapy Alone in Previously Untreated Locally Advanced or Metastatic Urothelial Cancer No dispute reported 06/30/2026 733457781
Principal investigator 1 BeiGene, Ltd. $12,329.42 10/19/2020 Non-covered Recipient Entity
CARTI Cancer Center
A Phase 2, Multicenter, Single-arm Study of Zanubrutinib (BGB-3111) in Patients with Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Intolerant of Prior Treatment with Ibrutinib No dispute reported 06/30/2026 752997229
Principal investigator 1 BeiGene, Ltd. $12,329.42 10/14/2020 Non-covered Recipient Entity
CARTI Cancer Center
A Phase 2, Multicenter, Single-arm Study of Zanubrutinib (BGB-3111) in Patients with Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Intolerant of Prior Treatment with Ibrutinib No dispute reported 06/30/2026 752997227
Principal investigator 1 BeiGene, Ltd. $1,838.40 10/08/2020 Non-covered Recipient Entity
Central Arkansas Radiation Therapy Institute, Inc
A Phase 3, Randomized Study of Zanubrutinib (BGB-3111) Compared With Ibrutinib in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma No dispute reported 06/30/2026 752997281
Principal investigator 1 BeiGene, Ltd. $12,329.42 10/06/2020 Non-covered Recipient Entity
CARTI Cancer Center
A Phase 2, Multicenter, Single-arm Study of Zanubrutinib (BGB-3111) in Patients with Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Intolerant of Prior Treatment with Ibrutinib No dispute reported 06/30/2026 752997225
Principal investigator 1 BeiGene, Ltd. $24,658.84 09/21/2020 Non-covered Recipient Entity
CARTI Cancer Center
A Phase 2, Multicenter, Single-arm Study of Zanubrutinib (BGB-3111) in Patients with Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Intolerant of Prior Treatment with Ibrutinib No dispute reported 06/30/2026 752997223
Principal investigator 1 Pharmacyclics LLC, An AbbVie Company $250.00 09/17/2020 Non-covered Recipient Entity
Central Arkansas Radiation Therapy Institute Carti Computed Tomography
PCYC-1134M-CA No dispute reported 06/30/2026 727733135
Principal investigator 1 Pharmacyclics LLC, An AbbVie Company $250.00 09/17/2020 Non-covered Recipient Entity
Central Arkansas Radiation Therapy Institute Carti Computed Tomography
PCYC-1134M-CA No dispute reported 06/30/2026 727733141
Principal investigator 1 Pharmacyclics LLC, An AbbVie Company $250.00 09/17/2020 Non-covered Recipient Entity
Central Arkansas Radiation Therapy Institute Carti Computed Tomography
PCYC-1134M-CA No dispute reported 06/30/2026 727733351
Principal investigator 1 Pharmacyclics LLC, An AbbVie Company $250.00 09/17/2020 Non-covered Recipient Entity
Central Arkansas Radiation Therapy Institute Carti Computed Tomography
PCYC-1134M-CA No dispute reported 06/30/2026 727734473
Principal investigator 1 Pharmacyclics LLC, An AbbVie Company $250.00 09/17/2020 Non-covered Recipient Entity
Central Arkansas Radiation Therapy Institute Carti Computed Tomography
PCYC-1134M-CA No dispute reported 06/30/2026 727734481
Principal investigator 1 Pharmacyclics LLC, An AbbVie Company $250.00 09/17/2020 Non-covered Recipient Entity
Central Arkansas Radiation Therapy Institute Carti Computed Tomography
PCYC-1134M-CA No dispute reported 06/30/2026 727734867
Principal investigator 1 Pharmacyclics LLC, An AbbVie Company $250.00 09/17/2020 Non-covered Recipient Entity
Central Arkansas Radiation Therapy Institute Carti Computed Tomography
PCYC-1134M-CA No dispute reported 06/30/2026 727734871
Principal investigator 1 Pharmacyclics LLC, An AbbVie Company $250.00 09/17/2020 Non-covered Recipient Entity
Central Arkansas Radiation Therapy Institute Carti Computed Tomography
PCYC-1134M-CA No dispute reported 06/30/2026 727736023
Principal investigator 1 Pharmacyclics LLC, An AbbVie Company $250.00 09/17/2020 Non-covered Recipient Entity
Central Arkansas Radiation Therapy Institute Carti Computed Tomography
PCYC-1134M-CA No dispute reported 06/30/2026 727736026
Principal investigator 1 Eli Lilly and Company $12,300.00 09/14/2020 Non-covered Recipient Entity
CENTRAL ARKANSAS RADIATION
A MULTICENTER, OPEN-LABEL, RANDOMIZED-CONTROLLED STUDY OF ABEMACICLIB, A CDK4 AND 6 INHIBITOR, IN COMBINATION WITH FULVESTRANT COMPARED TO CHEMOTHERAPY IN WOMEN WITH HR POSITIVE, HER2 NEGATIVE METASTATIC BREAST CANCER WITH VISCERAL METASTASES No dispute reported 06/30/2026 728732595
Principal investigator 1 BeiGene, Ltd. $1,664.40 09/10/2020 Non-covered Recipient Entity
Central Arkansas Radiation Therapy Institute, Inc
A Phase 3, Randomized Study of Zanubrutinib (BGB-3111) Compared With Ibrutinib in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma No dispute reported 06/30/2026 752997267
Principal investigator 1 BeiGene, Ltd. $1,664.40 09/10/2020 Non-covered Recipient Entity
Central Arkansas Radiation Therapy Institute, Inc
A Phase 3, Randomized Study of Zanubrutinib (BGB-3111) Compared With Ibrutinib in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma No dispute reported 06/30/2026 752997269
Principal investigator 1 BeiGene, Ltd. $528.00 09/10/2020 Non-covered Recipient Entity
Central Arkansas Radiation Therapy Institute, Inc
A Phase 3, Randomized Study of Zanubrutinib (BGB-3111) Compared With Ibrutinib in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma No dispute reported 06/30/2026 752997285
Principal investigator 1 BeiGene, Ltd. $842.40 09/10/2020 Non-covered Recipient Entity
Central Arkansas Radiation Therapy Institute, Inc
A Phase 3, Randomized Study of Zanubrutinib (BGB-3111) Compared With Ibrutinib in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma No dispute reported 06/30/2026 752997287
Principal investigator 1 BeiGene, Ltd. $850.80 09/10/2020 Non-covered Recipient Entity
Central Arkansas Radiation Therapy Institute, Inc
A Phase 3, Randomized Study of Zanubrutinib (BGB-3111) Compared With Ibrutinib in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma No dispute reported 06/30/2026 752997289
Principal investigator 1 BeiGene, Ltd. $350.00 09/10/2020 Non-covered Recipient Entity
Central Arkansas Radiation Therapy Institute, Inc
A Phase 3, Randomized Study of Zanubrutinib (BGB-3111) Compared With Ibrutinib in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma No dispute reported 06/30/2026 752997291
Principal investigator 1 BeiGene, Ltd. $1,000.00 09/10/2020 Non-covered Recipient Entity
Central Arkansas Radiation Therapy Institute, Inc
A Phase 3, Randomized Study of Zanubrutinib (BGB-3111) Compared With Ibrutinib in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma No dispute reported 06/30/2026 752997293
Principal investigator 1 BeiGene, Ltd. $850.80 09/10/2020 Non-covered Recipient Entity
Central Arkansas Radiation Therapy Institute, Inc
A Phase 3, Randomized Study of Zanubrutinib (BGB-3111) Compared With Ibrutinib in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma No dispute reported 06/30/2026 752997295
Principal investigator 1 BeiGene, Ltd. $528.00 09/10/2020 Non-covered Recipient Entity
Central Arkansas Radiation Therapy Institute, Inc
A Phase 3, Randomized Study of Zanubrutinib (BGB-3111) Compared With Ibrutinib in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma No dispute reported 06/30/2026 752997299
Principal investigator 1 BeiGene, Ltd. $842.40 09/10/2020 Non-covered Recipient Entity
Central Arkansas Radiation Therapy Institute, Inc
A Phase 3, Randomized Study of Zanubrutinib (BGB-3111) Compared With Ibrutinib in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma No dispute reported 06/30/2026 752997301
Principal investigator 1 BeiGene, Ltd. $1,000.00 09/10/2020 Non-covered Recipient Entity
Central Arkansas Radiation Therapy Institute, Inc
A Phase 3, Randomized Study of Zanubrutinib (BGB-3111) Compared With Ibrutinib in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma No dispute reported 06/30/2026 752997303
Principal investigator 1 BeiGene, Ltd. $350.00 09/10/2020 Non-covered Recipient Entity
Central Arkansas Radiation Therapy Institute, Inc
A Phase 3, Randomized Study of Zanubrutinib (BGB-3111) Compared With Ibrutinib in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma No dispute reported 06/30/2026 752997305
Principal investigator 1 BeiGene, Ltd. $550.00 09/10/2020 Non-covered Recipient Entity
Central Arkansas Radiation Therapy Institute, Inc
A Phase 3, Randomized Study of Zanubrutinib (BGB-3111) Compared With Ibrutinib in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma No dispute reported 06/30/2026 752997307
Principal investigator 1 BeiGene, Ltd. $702.00 09/10/2020 Non-covered Recipient Entity
Central Arkansas Radiation Therapy Institute, Inc
A Phase 3, Randomized Study of Zanubrutinib (BGB-3111) Compared With Ibrutinib in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma No dispute reported 06/30/2026 752997309
Principal investigator 1 BeiGene, Ltd. $550.00 09/10/2020 Non-covered Recipient Entity
Central Arkansas Radiation Therapy Institute, Inc
A Phase 3, Randomized Study of Zanubrutinib (BGB-3111) Compared With Ibrutinib in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma No dispute reported 06/30/2026 752997311
Principal investigator 1 BeiGene, Ltd. $702.00 09/10/2020 Non-covered Recipient Entity
Central Arkansas Radiation Therapy Institute, Inc
A Phase 3, Randomized Study of Zanubrutinib (BGB-3111) Compared With Ibrutinib in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma No dispute reported 06/30/2026 752997313
Principal investigator 1 BeiGene, Ltd. $49,317.68 09/03/2020 Non-covered Recipient Entity
CARTI Cancer Center
A Phase 2, Multicenter, Single-arm Study of Zanubrutinib (BGB-3111) in Patients with Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Intolerant of Prior Treatment with Ibrutinib No dispute reported 06/30/2026 752997221
Principal investigator 1 CHIESI USA, INC. $50.00 09/02/2020 Non-covered Recipient Entity
CENTRAL ARKANSAS RADIATION THERAPY
CUSA-081-HEM-01 No dispute reported 06/30/2026 751488551
Principal investigator 1 CHIESI USA, INC. $75.00 09/02/2020 Non-covered Recipient Entity
CENTRAL ARKANSAS RADIATION THERAPY
CUSA-081-HEM-01 No dispute reported 06/30/2026 751488953
Principal investigator 1 CHIESI USA, INC. $138.00 09/02/2020 Non-covered Recipient Entity
CENTRAL ARKANSAS RADIATION THERAPY
CUSA-081-HEM-01 No dispute reported 06/30/2026 751488959
Principal investigator 1 CHIESI USA, INC. $207.00 09/02/2020 Non-covered Recipient Entity
CENTRAL ARKANSAS RADIATION THERAPY
CUSA-081-HEM-01 No dispute reported 06/30/2026 751489047
Principal investigator 1 Pharmacyclics LLC, An AbbVie Company $250.00 08/25/2020 Non-covered Recipient Entity
Central Arkansas Radiation Therapy Institute Carti Computed Tomography
PCYC-1134M-CA No dispute reported 06/30/2026 727733371
Principal investigator 1 Pharmacyclics LLC, An AbbVie Company $250.00 08/25/2020 Non-covered Recipient Entity
Central Arkansas Radiation Therapy Institute Carti Computed Tomography
PCYC-1134M-CA No dispute reported 06/30/2026 727734035
Principal investigator 1 Pharmacyclics LLC, An AbbVie Company $250.00 08/25/2020 Non-covered Recipient Entity
Central Arkansas Radiation Therapy Institute Carti Computed Tomography
PCYC-1134M-CA No dispute reported 06/30/2026 727734130
Principal investigator 1 Pharmacyclics LLC, An AbbVie Company $250.00 08/25/2020 Non-covered Recipient Entity
Central Arkansas Radiation Therapy Institute Carti Computed Tomography
PCYC-1134M-CA No dispute reported 06/30/2026 727734265
Principal investigator 1 Pharmacyclics LLC, An AbbVie Company $250.00 08/25/2020 Non-covered Recipient Entity
Central Arkansas Radiation Therapy Institute Carti Computed Tomography
PCYC-1134M-CA No dispute reported 06/30/2026 727734279
Principal investigator 1 BeiGene, Ltd. $12,329.42 08/24/2020 Non-covered Recipient Entity
CARTI Cancer Center
A Phase 2, Multicenter, Single-arm Study of Zanubrutinib (BGB-3111) in Patients with Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Intolerant of Prior Treatment with Ibrutinib No dispute reported 06/30/2026 752997219
Principal investigator 1 Amgen Inc. $925.00 08/21/2020 Non-covered Recipient Entity
CARTI CANCER CENTER
Prospective Observational Study of Onpro vs SOC. No dispute reported 06/30/2026 731641611
Principal investigator 1 CHIESI USA, INC. $243.75 08/21/2020 Non-covered Recipient Entity
CENTRAL ARKANSAS RADIATION THERAPY
CUSA-081-HEM-01 No dispute reported 06/30/2026 751488263
Principal investigator 1 CHIESI USA, INC. $2,098.00 08/21/2020 Non-covered Recipient Entity
CENTRAL ARKANSAS RADIATION THERAPY
CUSA-081-HEM-01 No dispute reported 06/30/2026 751488269
Principal investigator 1 BeiGene, Ltd. $12,329.42 08/19/2020 Non-covered Recipient Entity
CARTI Cancer Center
A Phase 2, Multicenter, Single-arm Study of Zanubrutinib (BGB-3111) in Patients with Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Intolerant of Prior Treatment with Ibrutinib No dispute reported 06/30/2026 752997217
Principal investigator 1 BeiGene, Ltd. $3,343.20 08/13/2020 Non-covered Recipient Entity
Central Arkansas Radiation Therapy Institute, Inc
A Phase 3, Randomized Study of Zanubrutinib (BGB-3111) Compared With Ibrutinib in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma No dispute reported 06/30/2026 752997271
Principal investigator 1 BeiGene, Ltd. $3,343.20 08/13/2020 Non-covered Recipient Entity
Central Arkansas Radiation Therapy Institute, Inc
A Phase 3, Randomized Study of Zanubrutinib (BGB-3111) Compared With Ibrutinib in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma No dispute reported 06/30/2026 752997273
Principal investigator 1 BeiGene, Ltd. $12,329.42 07/27/2020 Non-covered Recipient Entity
CARTI Cancer Center
A Phase 2, Multicenter, Single-arm Study of Zanubrutinib (BGB-3111) in Patients with Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Intolerant of Prior Treatment with Ibrutinib No dispute reported 06/30/2026 752997215
Principal investigator 1 BeiGene, Ltd. $12,329.42 07/22/2020 Non-covered Recipient Entity
CARTI Cancer Center
A Phase 2, Multicenter, Single-arm Study of Zanubrutinib (BGB-3111) in Patients with Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Intolerant of Prior Treatment with Ibrutinib No dispute reported 06/30/2026 752997213
Principal investigator 1 Pharmacyclics LLC, An AbbVie Company $250.00 07/21/2020 Non-covered Recipient Entity
Central Arkansas Radiation Therapy Institute Carti Computed Tomography
PCYC-1134M-CA No dispute reported 06/30/2026 727735345
Principal investigator 1 Pharmacyclics LLC, An AbbVie Company $250.00 07/21/2020 Non-covered Recipient Entity
Central Arkansas Radiation Therapy Institute Carti Computed Tomography
PCYC-1134M-CA No dispute reported 06/30/2026 727736051
Principal investigator 1 BeiGene, Ltd. $12,329.42 07/14/2020 Non-covered Recipient Entity
CARTI Cancer Center
A Phase 2, Multicenter, Single-arm Study of Zanubrutinib (BGB-3111) in Patients with Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Intolerant of Prior Treatment with Ibrutinib No dispute reported 06/30/2026 752997211
Principal investigator 1 BeiGene, Ltd. $4,858.80 07/14/2020 Non-covered Recipient Entity
Central Arkansas Radiation Therapy Institute, Inc
A Phase 3, Randomized Study of Zanubrutinib (BGB-3111) Compared With Ibrutinib in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma No dispute reported 06/30/2026 752997275
Principal investigator 1 BeiGene, Ltd. $4,858.80 07/14/2020 Non-covered Recipient Entity
Central Arkansas Radiation Therapy Institute, Inc
A Phase 3, Randomized Study of Zanubrutinib (BGB-3111) Compared With Ibrutinib in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma No dispute reported 06/30/2026 752997277
Principal investigator 1 BeiGene, Ltd. $24,658.84 06/29/2020 Non-covered Recipient Entity
CARTI Cancer Center
A Phase 2, Multicenter, Single-arm Study of Zanubrutinib (BGB-3111) in Patients with Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Intolerant of Prior Treatment with Ibrutinib No dispute reported 06/30/2026 752997209
Principal investigator 1 BeiGene, Ltd. $49,317.68 06/25/2020 Non-covered Recipient Entity
CARTI Cancer Center
A Phase 2, Multicenter, Single-arm Study of Zanubrutinib (BGB-3111) in Patients with Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Intolerant of Prior Treatment with Ibrutinib No dispute reported 06/30/2026 752997207
Principal investigator 1 Pharmacyclics LLC, An AbbVie Company $250.00 06/18/2020 Non-covered Recipient Entity
Central Arkansas Radiation Therapy Institute Carti Computed Tomography
PCYC-1134M-CA No dispute reported 06/30/2026 727729245
Principal investigator 1 Pharmacyclics LLC, An AbbVie Company $250.00 06/18/2020 Non-covered Recipient Entity
Central Arkansas Radiation Therapy Institute Carti Computed Tomography
PCYC-1134M-CA No dispute reported 06/30/2026 727729253
Principal investigator 1 Pharmacyclics LLC, An AbbVie Company $250.00 06/16/2020 Non-covered Recipient Entity
Central Arkansas Radiation Therapy Institute Carti Computed Tomography
PCYC-1134M-CA No dispute reported 06/30/2026 727730463
Principal investigator 1 Pharmacyclics LLC, An AbbVie Company $250.00 06/16/2020 Non-covered Recipient Entity
Central Arkansas Radiation Therapy Institute Carti Computed Tomography
PCYC-1134M-CA No dispute reported 06/30/2026 727730465
Principal investigator 1 BeiGene, Ltd. $1,719.60 06/09/2020 Non-covered Recipient Entity
Central Arkansas Radiation Therapy Institute, Inc
A Phase 3, Randomized Study of Zanubrutinib (BGB-3111) Compared With Ibrutinib in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma No dispute reported 06/30/2026 752997263
Principal investigator 1 BeiGene, Ltd. $1,719.60 06/09/2020 Non-covered Recipient Entity
Central Arkansas Radiation Therapy Institute, Inc
A Phase 3, Randomized Study of Zanubrutinib (BGB-3111) Compared With Ibrutinib in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma No dispute reported 06/30/2026 752997265
Principal investigator 1 Pharmacyclics LLC, An AbbVie Company $250.00 06/02/2020 Non-covered Recipient Entity
Central Arkansas Radiation Therapy Institute Carti Computed Tomography
PCYC-1134M-CA No dispute reported 06/30/2026 727729863
Principal investigator 1 Pharmacyclics LLC, An AbbVie Company $250.00 06/02/2020 Non-covered Recipient Entity
Central Arkansas Radiation Therapy Institute Carti Computed Tomography
PCYC-1134M-CA No dispute reported 06/30/2026 727729867
Principal investigator 1 Pharmacyclics LLC, An AbbVie Company $250.00 06/02/2020 Non-covered Recipient Entity
Central Arkansas Radiation Therapy Institute Carti Computed Tomography
PCYC-1134M-CA No dispute reported 06/30/2026 727730263
Principal investigator 1 Pharmacyclics LLC, An AbbVie Company $250.00 06/02/2020 Non-covered Recipient Entity
Central Arkansas Radiation Therapy Institute Carti Computed Tomography
PCYC-1134M-CA No dispute reported 06/30/2026 727730531
Principal investigator 1 Pharmacyclics LLC, An AbbVie Company $250.00 06/02/2020 Non-covered Recipient Entity
Central Arkansas Radiation Therapy Institute Carti Computed Tomography
PCYC-1134M-CA No dispute reported 06/30/2026 727730535
Principal investigator 1 Pharmacyclics LLC, An AbbVie Company $250.00 06/02/2020 Non-covered Recipient Entity
Central Arkansas Radiation Therapy Institute Carti Computed Tomography
PCYC-1134M-CA No dispute reported 06/30/2026 727730775
Principal investigator 1 Pharmacyclics LLC, An AbbVie Company $250.00 06/02/2020 Non-covered Recipient Entity
Central Arkansas Radiation Therapy Institute Carti Computed Tomography
PCYC-1134M-CA No dispute reported 06/30/2026 727730779
Principal investigator 1 Pharmacyclics LLC, An AbbVie Company $250.00 06/02/2020 Non-covered Recipient Entity
Central Arkansas Radiation Therapy Institute Carti Computed Tomography
PCYC-1134M-CA No dispute reported 06/30/2026 727730799
Principal investigator 1 Pharmacyclics LLC, An AbbVie Company $250.00 06/02/2020 Non-covered Recipient Entity
Central Arkansas Radiation Therapy Institute Carti Computed Tomography
PCYC-1134M-CA No dispute reported 06/30/2026 727730843
Principal investigator 1 Pharmacyclics LLC, An AbbVie Company $250.00 06/02/2020 Non-covered Recipient Entity
Central Arkansas Radiation Therapy Institute Carti Computed Tomography
PCYC-1134M-CA No dispute reported 06/30/2026 727730971
Principal investigator 1 Pharmacyclics LLC, An AbbVie Company $250.00 06/02/2020 Non-covered Recipient Entity
Central Arkansas Radiation Therapy Institute Carti Computed Tomography
PCYC-1134M-CA No dispute reported 06/30/2026 727730989
Principal investigator 1 Pharmacyclics LLC, An AbbVie Company $250.00 06/02/2020 Non-covered Recipient Entity
Central Arkansas Radiation Therapy Institute Carti Computed Tomography
PCYC-1134M-CA No dispute reported 06/30/2026 727731032
Principal investigator 1 Pharmacyclics LLC, An AbbVie Company $250.00 06/02/2020 Non-covered Recipient Entity
Central Arkansas Radiation Therapy Institute Carti Computed Tomography
PCYC-1134M-CA No dispute reported 06/30/2026 727731035
Principal investigator 1 Pharmacyclics LLC, An AbbVie Company $250.00 06/02/2020 Non-covered Recipient Entity
Central Arkansas Radiation Therapy Institute Carti Computed Tomography
PCYC-1134M-CA No dispute reported 06/30/2026 727731039
Principal investigator 1 Pharmacyclics LLC, An AbbVie Company $250.00 06/02/2020 Non-covered Recipient Entity
Central Arkansas Radiation Therapy Institute Carti Computed Tomography
PCYC-1134M-CA No dispute reported 06/30/2026 727731045
Principal investigator 1 Pharmacyclics LLC, An AbbVie Company $250.00 06/02/2020 Non-covered Recipient Entity
Central Arkansas Radiation Therapy Institute Carti Computed Tomography
PCYC-1134M-CA No dispute reported 06/30/2026 727732039
Principal investigator 1 BeiGene, Ltd. $2,450.00 05/05/2020 Non-covered Recipient Entity
Central Arkansas Radiation Therapy Institute, Inc
A Phase 3, Randomized Study of Zanubrutinib (BGB-3111) Compared With Ibrutinib in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma No dispute reported 06/30/2026 752997239
Principal investigator 1 BeiGene, Ltd. $864.00 05/05/2020 Non-covered Recipient Entity
Central Arkansas Radiation Therapy Institute, Inc
A Phase 3, Randomized Study of Zanubrutinib (BGB-3111) Compared With Ibrutinib in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma No dispute reported 06/30/2026 752997241
Principal investigator 1 BeiGene, Ltd. $500.00 05/05/2020 Non-covered Recipient Entity
Central Arkansas Radiation Therapy Institute, Inc
A Phase 3, Randomized Study of Zanubrutinib (BGB-3111) Compared With Ibrutinib in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma No dispute reported 06/30/2026 752997243
Principal investigator 1 BeiGene, Ltd. $1,000.00 05/05/2020 Non-covered Recipient Entity
Central Arkansas Radiation Therapy Institute, Inc
A Phase 3, Randomized Study of Zanubrutinib (BGB-3111) Compared With Ibrutinib in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma No dispute reported 06/30/2026 752997245
Principal investigator 1 BeiGene, Ltd. $1,000.00 05/05/2020 Non-covered Recipient Entity
Central Arkansas Radiation Therapy Institute, Inc
A Phase 3, Randomized Study of Zanubrutinib (BGB-3111) Compared With Ibrutinib in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma No dispute reported 06/30/2026 752997247
Principal investigator 1 BeiGene, Ltd. $500.00 05/05/2020 Non-covered Recipient Entity
Central Arkansas Radiation Therapy Institute, Inc
A Phase 3, Randomized Study of Zanubrutinib (BGB-3111) Compared With Ibrutinib in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma No dispute reported 06/30/2026 752997249
Principal investigator 1 BeiGene, Ltd. $864.00 05/05/2020 Non-covered Recipient Entity
Central Arkansas Radiation Therapy Institute, Inc
A Phase 3, Randomized Study of Zanubrutinib (BGB-3111) Compared With Ibrutinib in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma No dispute reported 06/30/2026 752997251
Principal investigator 1 BeiGene, Ltd. $1,500.00 05/05/2020 Non-covered Recipient Entity
Central Arkansas Radiation Therapy Institute, Inc
A Phase 3, Randomized Study of Zanubrutinib (BGB-3111) Compared With Ibrutinib in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma No dispute reported 06/30/2026 752997253
Principal investigator 1 BeiGene, Ltd. $2,450.00 05/05/2020 Non-covered Recipient Entity
Central Arkansas Radiation Therapy Institute, Inc
A Phase 3, Randomized Study of Zanubrutinib (BGB-3111) Compared With Ibrutinib in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma No dispute reported 06/30/2026 752997255
Principal investigator 1 BeiGene, Ltd. $1,684.80 05/05/2020 Non-covered Recipient Entity
Central Arkansas Radiation Therapy Institute, Inc
A Phase 3, Randomized Study of Zanubrutinib (BGB-3111) Compared With Ibrutinib in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma No dispute reported 06/30/2026 752997257
Principal investigator 1 BeiGene, Ltd. $1,500.00 05/05/2020 Non-covered Recipient Entity
Central Arkansas Radiation Therapy Institute, Inc
A Phase 3, Randomized Study of Zanubrutinib (BGB-3111) Compared With Ibrutinib in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma No dispute reported 06/30/2026 752997259
Principal investigator 1 BeiGene, Ltd. $1,684.80 05/05/2020 Non-covered Recipient Entity
Central Arkansas Radiation Therapy Institute, Inc
A Phase 3, Randomized Study of Zanubrutinib (BGB-3111) Compared With Ibrutinib in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma No dispute reported 06/30/2026 752997261
Principal investigator 1 CHIESI USA, INC. $6,300.00 04/08/2020 Non-covered Recipient Entity
CENTRAL ARKANSAS RADIATION THERAPY
CUSA-081-HEM-01 No dispute reported 06/30/2026 751488521
Principal investigator 1 CHIESI USA, INC. $2,000.00 04/08/2020 Non-covered Recipient Entity
CENTRAL ARKANSAS RADIATION THERAPY
CUSA-081-HEM-01 No dispute reported 06/30/2026 751488781
Principal investigator 1 Pharmacyclics LLC, An AbbVie Company $250.00 03/10/2020 Non-covered Recipient Entity
Central Arkansas Radiation Therapy Institute Carti Computed Tomography
PCYC-1134M-CA No dispute reported 06/30/2026 727725029
Principal investigator 1 Pharmacyclics LLC, An AbbVie Company $250.00 03/10/2020 Non-covered Recipient Entity
Central Arkansas Radiation Therapy Institute Carti Computed Tomography
PCYC-1134M-CA No dispute reported 06/30/2026 727725062
Principal investigator 1 Pharmacyclics LLC, An AbbVie Company $250.00 03/10/2020 Non-covered Recipient Entity
Central Arkansas Radiation Therapy Institute Carti Computed Tomography
PCYC-1134M-CA No dispute reported 06/30/2026 727725547
Principal investigator 1 Pharmacyclics LLC, An AbbVie Company $250.00 03/10/2020 Non-covered Recipient Entity
Central Arkansas Radiation Therapy Institute Carti Computed Tomography
PCYC-1134M-CA No dispute reported 06/30/2026 727726391
Principal investigator 1 Pharmacyclics LLC, An AbbVie Company $250.00 03/10/2020 Non-covered Recipient Entity
Central Arkansas Radiation Therapy Institute Carti Computed Tomography
PCYC-1134M-CA No dispute reported 06/30/2026 727726395
Principal investigator 1 Pharmacyclics LLC, An AbbVie Company $250.00 03/10/2020 Non-covered Recipient Entity
Central Arkansas Radiation Therapy Institute Carti Computed Tomography
PCYC-1134M-CA No dispute reported 06/30/2026 727726401
Recipient Eli Lilly and Company $139.26 03/05/2020 Covered Recipient Physician A MULTICENTER, OPEN-LABEL, RANDOMIZED-CONTROLLED STUDY OF ABEMACICLIB, A CDK4 AND 6 INHIBITOR, IN COMBINATION WITH FULVESTRANT COMPARED TO CHEMOTHERAPY IN WOMEN WITH HR POSITIVE, HER2 NEGATIVE METASTATIC BREAST CANCER WITH VISCERAL METASTASES No dispute reported 06/30/2026 728723971
Principal investigator 1 Pharmacyclics LLC, An AbbVie Company $250.00 02/14/2020 Non-covered Recipient Entity
Central Arkansas Radiation Therapy Institute Carti Computed Tomography
PCYC-1134M-CA No dispute reported 06/30/2026 727725305
Principal investigator 1 Pharmacyclics LLC, An AbbVie Company $250.00 02/14/2020 Non-covered Recipient Entity
Central Arkansas Radiation Therapy Institute Carti Computed Tomography
PCYC-1134M-CA No dispute reported 06/30/2026 727725309
Principal investigator 1 Pharmacyclics LLC, An AbbVie Company $250.00 02/14/2020 Non-covered Recipient Entity
Central Arkansas Radiation Therapy Institute Carti Computed Tomography
PCYC-1134M-CA No dispute reported 06/30/2026 727725313
Principal investigator 1 Pharmacyclics LLC, An AbbVie Company $250.00 02/14/2020 Non-covered Recipient Entity
Central Arkansas Radiation Therapy Institute Carti Computed Tomography
PCYC-1134M-CA No dispute reported 06/30/2026 727725317
Principal investigator 1 Pharmacyclics LLC, An AbbVie Company $250.00 02/14/2020 Non-covered Recipient Entity
Central Arkansas Radiation Therapy Institute Carti Computed Tomography
PCYC-1134M-CA No dispute reported 06/30/2026 727725689
Principal investigator 1 Pharmacyclics LLC, An AbbVie Company $250.00 02/14/2020 Non-covered Recipient Entity
Central Arkansas Radiation Therapy Institute Carti Computed Tomography
PCYC-1134M-CA No dispute reported 06/30/2026 727726117
Principal investigator 1 Pharmacyclics LLC, An AbbVie Company $250.00 02/14/2020 Non-covered Recipient Entity
Central Arkansas Radiation Therapy Institute Carti Computed Tomography
PCYC-1134M-CA No dispute reported 06/30/2026 727726665
Principal investigator 1 Amgen Inc. $19,727.00 01/30/2020 Non-covered Recipient Entity
CENTRAL ARKANSAS RADIATION THERAPY INSTITUTE INC DBA CARTI
Prospective Observational Study of Onpro vs SOC. No dispute reported 06/30/2026 731641637
Principal investigator 1 Pharmacyclics LLC, An AbbVie Company $250.00 01/14/2020 Non-covered Recipient Entity
Central Arkansas Radiation Therapy Institute Carti Computed Tomography
PCYC-1134M-CA No dispute reported 06/30/2026 727725538
Principal investigator 1 Pharmacyclics LLC, An AbbVie Company $250.00 01/14/2020 Non-covered Recipient Entity
Central Arkansas Radiation Therapy Institute Carti Computed Tomography
PCYC-1134M-CA No dispute reported 06/30/2026 727725543
Principal investigator 1 Pharmacyclics LLC, An AbbVie Company $250.00 01/02/2020 Non-covered Recipient Entity
Central Arkansas Radiation Therapy Institute Carti Computed Tomography
PCYC-1134M-CA No dispute reported 06/30/2026 727725533
Principal investigator 1 Pharmacyclics LLC, An AbbVie Company $250.00 01/02/2020 Non-covered Recipient Entity
Central Arkansas Radiation Therapy Institute Carti Computed Tomography
PCYC-1134M-CA No dispute reported 06/30/2026 727726669
Principal investigator 1 Pharmacyclics LLC, An AbbVie Company $250.00 01/02/2020 Non-covered Recipient Entity
Central Arkansas Radiation Therapy Institute Carti Computed Tomography
PCYC-1134M-CA No dispute reported 06/30/2026 727726673
Principal investigator 1 Pharmacyclics LLC, An AbbVie Company $250.00 01/02/2020 Non-covered Recipient Entity
Central Arkansas Radiation Therapy Institute Carti Computed Tomography
PCYC-1134M-CA No dispute reported 06/30/2026 727726677